Health AI Central
Peer-Reviewed Publication
Hum Vaccin Immunother2026;22(1):2720966.December 1, 2026Journal Article

Parents' and caregivers' views on pediatric meningococcal disease and serogroup B vaccination.

Oscar Herrera-Restrepo1, Vasudha Gupta2, Sophie Jacobovitz2, Tosin Olaiya1, Elise Kuylen3, Karam Dahyaleh1, Lynn Kwock1, Thatiana Pinto3, Sofia B Pinto4, Suzanne Staebler5
1GSK, Philadelphia, PA, USA.
2IQVIA, Durham, NC, USA.
3GSK, Wavre, Belgium.
4GSK, Rio de Janeiro, Brazil.
5National Coalition for Infant Health, Washington DC, USA.
PubMed DOI

Abstract

In the United States (US), the highest incidence of invasive meningococcal disease (IMD) is among infants aged ≤ 1 year (y). While most IMD cases in US infants are caused by meningococcal serogroup B (MenB), there is no MenB vaccine approved or recommended for US children < 10 y. This study sought to understand general attitudes toward vaccination, knowledge of IMD, and MenB vaccine preferences am…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.